INTRODUCTION
For most surgeons postoperative follow-up comes naturally after primary surgery, but reliable evidence that this process improves overall survival is lacking. Despite tight resources follow-up remains routine. A 1995 US survey of different follow-up regimens showed a wide range of costs for five years of follow-up per patient (1); the cheapest they found was $900, while the most expensive was nearly $27,000. With a million follow-up visits generated by each year's cohort of new US cases, this amounts to billions spent, but for what benefit?
AIMS OF FOLLOW-UP
Traditionally, follow-up has had four main aims (2, 3), to which one more might be added:
EARLY DETECTION OF RECURRENCE OR NEW PRIMARY TUMOUR
Following radical surgery for colorectal cancer, up to 50 % of patients will develop local or distant recurrence of their cancer, and most will die as a direct result (4). Moreover, up to 8 % will develop a new (metachronous) primary malignancy (5, 6, 7), and in many more premalignant adenomas will form. Therefore attempts to detect such lesions at the earliest stage should be made -or so runs the logic of follow-up aimed at their presymptomatic identification.
But does a policy of regular, pro-active follow-up for all lead to more effective management of recur-rence compared to investigation at symptom onset? If not, Charles Moertel's reflection on CEA monitoring, enunciated 20 years ago, might be applied to the whole process of follow-up: "The only outcome for most patients the needless anxiety produced by premature knowledge of the presence of a fatal disease" (9).
MANAGEMENT OF POST-SURGICAL COMPLICATIONS
Identifying wound problems, providing supportive stoma care, attending to difficulties with bowel function and neurological deficits after rectal cancer surgery -all these require post-operative outpatient supervision. Most such issues can be resolved, or helped to the limit of possibility, within one year of surgery.
REASSURING PATIENTS
Patients' reactions to the cancer experience vary widely. Attitudes along the whole spectrum demand different approaches by the surgical team; and, in the absence of solid evidence of an oncological imperative for a particular follow-up regimen or individual tests, patients require different patterns of reassurance through post-operative patient/doctor contact.
AUDIT AND QUALITY CONTROL OF SURGICAL OUTCOMES
In a busy life with competing priorities, most surgeons have not seen the need to analyse the outcomes of their cancer surgery. Evolving societal expectations may force change here.
DECIDING UPON AND DELIVERING ADJUVANT THERAPY
As evidence for the efficacy of adjuvants in subgroups accumulates, this becomes a more widely applicable reason for continuing contact following surgery, though only initially with the surgeon. Further, as palliative chemotherapy and radiotherapy become more effective, particularly if evidence grows to suggest that treatment is more effective if given early in the natural history of recurrent disease, follow-up for early detection may have a more rational basis.
WHAT ARE THE KEY ELEMENTS OF THE FOLLOW-UP PROCESS?
Follow-up planning requires decisions about the frequency of surveillance visits, and their clinical and investigative content. There is an enormous range of possible combinations of visit frequencies and investigations that could be included; Kievit and Bruinvels recently computed that there are a mind-boggling 30,000 × 8 5 different protocols which could be generated from these variables (10). The major elements are as follows:
SIMPLE PATIENT/DOCTOR CONTACT This can range from symptom-prompted, or reactive, contact -with no planned, asymptomatic visits, through the more usual regular interview and physical examination, to frequent and expensive cycles of investigation. 'History and physical' may provide the first evidence in up to 50 % of patients with recurrence (11). Intervals between visits vary depending on the time since surgery and the attitude of the clinician; as most recurrences manifest within two years (12), most regimens concentrate on this period, with continuing though less frequent visits till five years after operation. Some argue that follow-up should continue indefinitely (2). Each patient will make 12-15 visits over a five year period (10). However, most symptomatic recurrences become apparent to the patient between pre-planned visits, leading either to unplanned urgent visits (making the planned programme irrelevant) or to unwarranted delay until the next planned visit -a delay which, of course, may or may not matter! Simple outpatient contact includes symptomatic enquiry, and physical examination. Investigations may be prompted either by symptoms and signs, or be part of a planned surveillance programme; the discussion of investigative techniques in subsequent sections applies specifically to the latter.
SERUM TUMOUR MARKERS
Many surgeons world wide use serum CEA measurement in follow-up. In the USA, it was estimated that 500,000 patients are undergoing serial CEA monitoring at any one time (13), offering the prospect of recurrence detection on average six months before the onset of symptoms. There can be no doubt that this modality leads to earlier diagnosis and more second look surgery (14), but evidence that this approach improves the survivability of recurrent disease is very thin. This may be resolved when the results of the only randomised trial in the field are published in the near future (15).
Serial measurement of serum markers after primary surgery to predict recurrence, and hence to indi-cate those who might be candidates for second look surgery, has been studied intensively; Moertel estimated that at any one time, 500,000 Americans are being sampled serially in order to predict recurrence prior to the onset of symptoms (13). There has been continuing advocacy of second look surgery based on serum markers, CEA in particular (16) . So what is the evidence that serial CEA follow-up as an indicator for second look surgery might alter prognosis favourably? Should such a policy be adopted universally?
Serum CEA rises in the majority of cases before the onset of symptoms and signs (17) ; amongst more than 2000 cases described in series published in the early 1980s, 75 % demonstrated a CEA rise as first indicator of recurrent disease (18) . In the mid 1970s, there were several reports that regular monitoring led to early diagnosis of recurrence, up to 30 months before symptoms occurred (19) (20) (21) (22) . Using historical controls, it was suggested that early re-operation relying on CEA results as the sole indicator for surgery led to macroscopic clearance of recurrence in more patients (63 % compared to 27 % in a symptom-led second look cohort) (14, 16). Other non-randomised studies came to similar conclusions, while others differed on its utility (23) (24) (25) (26) (27) (28) (29) (30) (31) .
CEA assay has deficiencies in sensitivity and specificity. Most CEA rises herald the discovery of unresectable hepatic recurrence, while in 10-25 % of patients the raised CEA is 'falsely' positive, i.e. is not due to recurrent cancer (13, 32-35) leading to negative laparotomy if acted upon. Conversely a high proportion of patients have incurable disease at surgery (35) (36) . Efforts to improve the efficacy of CEA monitoring led to its combination with other tumour markers, but without significantly improved clinical utility (37) .
Fletcher pointed out that "Americans have valued cure at almost any cost", while suggesting that society could not be expected to pay for it (38) . In the absence of prospective control data it remained impossible to demonstrate any survival advantage from a policy of CEA-led second look surgery. A trial (under the auspices of the UK Cancer Research Campaign, and initially funded by the US National Institutes of Health) was set up in the United Kingdom in the 1980s: its design optimised power and minimised sample size through the use of late randomisation, at the time of CEA rise. Thus the therapeutic effect -if any -was more likely to be detected by excluding from randomisation those individuals in whom no events occurred during follow-up (15). In the Trial, patients were registered with the Trial Centre after primary surgery, after obtaining fully informed consent for participation in the full protocol. Patients were offered monthly CEA assay as well as conventional clinical follow-up, and were told that their clinician would not be informed of routine, normal results. Clinical follow-up conformed with the broad norm used in the United Kingdom. Randomisation was performed at the Trial Centre only after a significant CEA rise as defined by the Trial CEA algorithm. Clinicians were only informed of the CEA rise if the patient was ran-domised to the "Aggressive" arm, leading to workup towards second look surgery. Patients in the "Conventional" arm continued to receive standard clinical follow-up, their clinicians remaining unaware of the CEA rise or the randomisation. In any patient at any stage (including, of course, patients already randomised to the Conventional arm) in whom clinical evidence of recurrent disease became apparent, the clinician was at liberty to advise further surgery. Using this powerful trial design it was possible to seek evidence of a survival effect at a fixed time point after randomisation as a result of the introduction of a single item of data into clinical management, namely a raised CEA level. The trial recruited almost 1500 patients, and closed in 1993. After an appropriate length of follow-up of all cases, data analysis is almost complete, so that the results should be published shortly.
Other prognostic serum markers have been developed and used in the same way as CEA, including tissue polypeptide antigen (TPA), CA 19-9 and CA 50. There have been variable reports on their relative sensitivity and specificity compared to each other, to CEA and to combinations of markers (37, 39) .
In summary, CEA and other serum markers are sensitive, presymptomatic indicators of recurrent disease, but unless more effective methods of treatment can be triggered by a raised marker level, their diagnostic ability offers no more to most patients and their attendants than protracted prior knowledge of a fatal outcome for most patients, as suggested a generation ago by Charles Moertel (9).
FLEXIBLE ENDOSCOPY
In theory, at least, flexible endoscopy can play a part in two aspects of follow-up -detection of metachronous neoplasia, both benign and malignant, and recognition of recurrent cancer.
Detection and removal of metachronous adenomas might cut the incidence and mortality of metachronous cancer (40) , which has been reported as having a better outlook than the initial malignancy (41) . Some have found high yields of adenomas, including the larger lesions more likely to progress to cancer, with lesions found in up to 56 % of cases in untargeted follow-up (42-43) though the unselected rate is likely to be much less (44) . Metachronous cancer in the days before colonoscopic surveillance was reported in around 3-4 % of postoperative cases (45) . Some modern series quote rates of only 0.2-3 % (44), perhaps resulting from a true decrease due to polypectomy during surveillance, though such comparisons are very difficult.
Since most recurrences begin outside the bowel lumen, endoscopy is relatively insensitive as a method for the detection of recurrent cancer (1). Audisio's series indicated that colonoscopy yielded the first evidence of recurrence in less than 1 % of cases (12), though others have reported detection rates of up to 3-4 % (42, 44, (46) (47) .
The case for more frequent investigation than three yearly in capable endoscopic hands was not accepted by the group providing guidance for the UK Na-tional Health Service (48) , who felt, however, that a strong case could be made for establishing a 'clean colon' colonoscopically either before surgery or within six months of primary treatment. SCANNING Scanning modalities have become quite sensitive to small volume recurrent disease in the past decade, and may be applied in follow-up to identify local or distant recurrence. As most local recurrences begin extraluminally, scanning is certainly more useful than endoscopy or luminal contrast studies.
Local recurrence
Ultrasound (US) is more informative in, and close to, the bowel wall, while CT and MR are more sensitive to disease in the surrounding pelvic cavity. In two series comprising 168 patients in total, US was the sole indicator of recurrence in 6 of 23 cases (49-50). The deeper focal length of endoluminal MR may lead to its preferred use in this context (51) . A major difficulty with these three scanning modalities in the diagnosis of local recurrence is the differentiation of post-surgical changes from recurrent cancer; serial scanning, allowing recognition of increase in size and configuration of abnormal areas may be more useful than 'one-off' examination (52) . The development of monoclonal antibody imaging (radio-immunoscintigraphy, RIS) and positron emission tomography (PET) scanning have allowed functional discrimination of malignant from scar tissue as a criterion in differential diagnosis (53) .
Liver metastasis
Despite being very considerably cheaper and more portable, US is nevertheless able to achieve sensitivity and specificity that compare well with the other modalities, detecting lesions of one cm diameter (52) . The technology is well developed, so the key question becomes clinical utility, in particular any benefit gained from presymptomatic diagnosis. This will be discussed below.
OUTCOME AND COSTS OF FOLLOW-UP PROGRAMMES
Kievet and Bruinvels' four "conditions of benefice" provided objectivity in trying to assess the usefulness of routine follow-up (Table 1) (10). They offer a realistic balance between trying to identify and help the curable few, a compassionate and sensible approach for the incurable majority, and a realistic eye on cost.
There have been two broad approaches to this debate, the broadly descriptive review and the more focused randomised comparison. During 2002 two meta-analyses and a 'number needed to treat' (NNT) analysis have added further angles on the complex scene (54) (55) (56) . Follow-up after curative surgery for colorectal cancer
DESCRIPTIVE REVIEWS
The simple descriptive approach attempts to describe programmes in terms of their content, intensity and cost, and to try to detect differences in outcome by inference. Virgo and her colleagues made an attempt to collect, describe and assess the relative merits of 11 US surveillance strategies (1). Their main conclusion was that there is a wide range of cost without any indication that "higher cost strategies increase survival or quality of life." While cost is easy to compare between regimens, (range $910-$26,717, a 28-fold difference) clinical outcome comparison is much more difficult. Perhaps the most reasonable inference is that clinical outcome varies less than cost. Richard and McLeod compiled a much larger list of studies and programmes by performing a Medline search spanning 30 years (57). They studied regimens according to their statistical and epidemiological quality, separating cohort studies from the few extant randomised trials. Their comprehensive and definitive exploration of this very difficult field led them to the disappointing and inevitably vague judgement that "there is inconclusive evidence either to support or to refute the value of follow-up surveillance programs to detect recurrence of colorectal cancer." They point out importantly that existing data have not excluded an intensity-related effect of follow-up on cancer outcomes. These two large overviews, necessarily covering a very wide range of programmes, patient groups and clinical environments, both concluded that large randomised trials would be necessary to detect any realistic beneficial effect.
THE RANDOMISED TRIALS
Five randomised trials published in recent years have sought to compare the efficacy of different followup programmes, but have been similarly guarded in their conclusions (58-62) ( Table 2 ). It would have been predicted a priori that none of these trials had sufficient patients (range 106-597), and hence sufficient statistical power, to detect a realistic difference in survival. This proved to be the case -except for the Italian trial, in which with just 207 patients an absolute difference in five year survival between intensive and less intensive regimens yielded survivals of 73 % and 58 % respectively (p = 0.02) (62).
META-ANALYSES
Beart's group performed what they describe as a meta-analysis, but analysed three non-randomised studies together with two of the above-quoted RCTs (63) . They demonstrated a 2.5 times excess of surgery for recurrence and a 1.16 times excess survival in the intensive follow-up group. Their effort to add power to the investigation of this issue was clearly well placed, but the inclusion of non-randomised data prevented definitive conclusions. Their assertion that targeting of follow-up to higher risk groups "will make follow-up a cost-effective endeavour" begged the inference that it was not cost effective as presently applied to the mass of the post-surgical population. Three important publications in 2002 have opened up the debate. Meta-analyses of the five randomised trials have concluded that "there is an overall survival benefit for intensifying follow-up" (54) , and that "intensive follow-up. . . improves survival" (55) . Both reviews further conclude that it is not possible to define the optimum regimen (environment, frequency, investigations), and that large randomised trials are still needed to answer outstanding questions.
Kievit's number-needed-to-treat (NNT) analysis included data from the follow-up of over 36,000 patients (56) . He concluded that one long term survival as a result of early diagnosis through follow-up required 360 positive follow-up tests and eleven laparotomies. Other patients not so fortunate had either a 'neutral' outcome or were actually harmed. He suggested that in follow-up research there should be a move away from simple assessment of surgical curability of recurrence and towards assessing quality of life (QOL) outcomes and patient support, and that nurses and general practitioners should play a greater role in the follow-up process.
CONCLUSION
Until more solid evidence emerges to the contrary, in any health care system in which major decisions about funding are forced upon providers and consumers, the diffusion of improved primary surgical and colonoscopic technique across the clinical community and the application of population-based screening programmes are the options most likely to produce cost-effective improvements in outcomes. In the absence of more effective treatment methods, follow-up programmes aimed at early identification of recurrence should continue to come below these and many other priorities aimed at minimising the morbidity and mortality due to colorectal cancer. As an audit and research modality, and in the moral support of those who seek it, follow-up will continue to have a role. Most importantly, there is a need for much larger randomised trials (some are underway) which pay greater attention to QOL and to defining the roles of individual follow-up methods. 
